Hayden E. Klein

The top population health article of 2024 focused on 5 drugs in shortage as we go into the new year. | Image credit: MQ-Illustrations – stock.adobe.com The top population health news of 2024 included efforts to reduce out-of-pocket drug costs, […]

The top IVBM® coverage of 2024 focused on improving care delivery, addressing obesity, and more. | Image Credit: © AJMC® In 2024, the Institute for Value-Based Medicine® (IVBM®) brought together leading experts to explore transformative strategies in health care. From

The top heart failure articles of 2024 reflect a growing focus on innovative treatments and preventative strategies to improve patient outcomes, especially for heart failure with preserved ejection fraction (HFpEF). From surgical interventions and medication breakthroughs to understanding the impacts

Research in Duchenne muscular dystrophy (DMD) has seen significant growth over the past 2 decades, according to a bibliometric analysis published in Frontiers in Immunology.1 The study, which examined more than 9000 publications between 2004 and 2023, highlights evolving research

Lexicon Pharmaceuticals received a complete response letter (CRL) from the FDA today, rejecting the company’s application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD), according

The Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) program is a team-based care model designed to address cardiovascular, kidney, and metabolic health risks in patients with type 2 diabetes or prediabetes. Developed by the University Hospitals Harrington

MRI-derived septal circumferential strain (ECC) emerged as a promising biomarker for detecting early impairments in cardiac function in boys with Duchenne muscular dystrophy (DMD), even before signs appear on traditional tests, in a recent study published in Diagnostics.1 Researchers at

The FDA has issued a clinical hold notice on PepGen’s phase 2 trial for PGN-EDO51, an investigational treatment for Duchenne muscular dystrophy (DMD), delaying its US launch.1 The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind,

Minimal residual disease (MRD) testing is becoming a pivotal tool in personalizing multiple myeloma treatment, explains Hans Lee, MD, director of multiple myeloma clinical research, associate professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer

In March, the FDA approved givinostat for boys aged 6 and older with DMD. | Image credit: hafakot – stock.adobe.com This year’s top stories on Duchenne muscular dystrophy (DMD) managed care included a novel imaging method for tracking disease progression,